Heart Center Research, LLC
Heart Center Research, LLC
Huntsville, Alabama, United States9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Arterial Occlusive Diseases, Body Weight, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, kidney disorder, kidney failure, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Recruiting | Phase 2 | 2026-10-08 | NCT07783802 | |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-10-05 | NCT07069738 | |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2026-10-05 | NCT06909565 | |
| Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | acute myocardial infarction | Enrolling by invitation | Phase 3 | 2026-07-23 | NCT04957719 | |
| AMPLATZER PFO Occluder Post Approval Study | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, atrial septal defect, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, congenital heart disease, heart disorder, heart septal defect, nervous system disorder, patent foramen ovale, stroke disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-03-11 | NCT03309332 | |
| Amplatzer Amulet LAAO vs. NOAC | Arrhythmias, Cardiac, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-02-10 | NCT04226547 | |
| Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery | Post-discharge Outcomes | Active, not recruiting | Not stated | 2025-06-13 | NCT07009340 | |
| Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts | cardiovascular disorder, congestive heart failure, heart disorder, heart failure | Recruiting | Phase 4 | 2024-01-29 | NCT06218199 | |
| LEADERS FREE II: BioFreedom™ Pivotal Study | acute coronary syndrome, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2021-02-03 | NCT02843633 |